0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Tolbutamide Mortality in the Six "Phenformin Clinics"

Holbrooke S. Seltzer, MD
JAMA. 1971;218(4):594. doi:10.1001/jama.1971.03190170072022.
Text Size: A A A
Published online

ABSTRACT

To the Editor.—  I had serenely awaited publication of the University Group Diabetes Program (UGDP) findings on phenformin (217:777-784, 1971), knowing that the acceptable mortality among patients treated with tolbutamide in the six "phenformin clinics" would largely exonerate it as a killer drug.I was therefore taken aback to find the tolbutamide data omitted from the report on the grounds that "... The mortality data for patients in the tolbutamide group in the six clinics administering phenformin were similar to, although not as conclusive as, the mortality data observed for patients in this treatment group in the other six clinics" (p 779). This statement is incompatible with the UGDP findings reproduced in the Table, in which values are collated for both all-cause and cardiovascular mortality in the five treatment groups in all 12 clinics, the first six "non-phenformin clinics," and the last six "phenformin clinics," respectively. In particular, the cardiovascular

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();